1. Home
  2. MGNX vs CHMI Comparison

MGNX vs CHMI Comparison

Compare MGNX & CHMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$3.59

Market Cap

115.8M

Sector

Health Care

ML Signal

HOLD

Logo Cherry Hill Mortgage Investment Corporation

CHMI

Cherry Hill Mortgage Investment Corporation

HOLD

Current Price

$2.66

Market Cap

93.0M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
MGNX
CHMI
Founded
2000
2012
Country
United States
United States
Employees
N/A
14
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
115.8M
93.0M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
MGNX
CHMI
Price
$3.59
$2.66
Analyst Decision
Buy
Buy
Analyst Count
5
2
Target Price
$4.60
$3.00
AVG Volume (30 Days)
852.2K
233.4K
Earning Date
05-12-2026
05-05-2026
Dividend Yield
N/A
14.98%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$149,500,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$16.14
$61.13
P/E Ratio
N/A
$139.30
Revenue Growth
N/A
N/A
52 Week Low
$1.12
$2.17
52 Week High
$3.88
$3.14

Technical Indicators

Market Signals
Indicator
MGNX
CHMI
Relative Strength Index (RSI) 66.91 52.96
Support Level $1.48 $2.49
Resistance Level N/A $2.74
Average True Range (ATR) 0.24 0.09
MACD 0.01 0.01
Stochastic Oscillator 70.00 69.74

Price Performance

Historical Comparison
MGNX
CHMI

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

About CHMI Cherry Hill Mortgage Investment Corporation

Cherry Hill Mortgage Investment Corp is a fully integrated, internally managed residential real estate finance company focused on acquiring, investing in and managing residential mortgage assets in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.

Share on Social Networks: